<DOC>
	<DOCNO>NCT00129207</DOCNO>
	<brief_summary>The purpose study investigate ketoconazole ( Nizoral ) affect pharmacokinetics ( study drug affect body broken ) pharmacodynamics ( study drug act body ) active ingredient study drug Velcade ( bortezomib ) .</brief_summary>
	<brief_title>Ketoconazole Administration : How Affected Body Broken Down How Acts Body When Used With Velcade</brief_title>
	<detailed_description />
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Male female patient 18 year age old , diagnosis advance solid tumor curative treatment high priority available Karnofsky Performance Status ( KPS ) equal great 70 % Normal liver function test ( aspartate transaminase [ AST ] alanine transaminase [ ALT ] equal less 2 x upper limit normal [ ULN ] ) Total bilirubin equal less 1.5 x ULN Calculated creatinine clearance equal great 50 mL/min Normal serum calcium Patients significant cardiac disease Equal great Grade 2 neuropathy Active hepatitis HIV infection Secondary malignancy Transfusiondependent receive extensive radiation therapy , systemic chemotherapy , antineoplastic therapy within 4 week enrollment Patients take concomitant medication inhibitory inducing activity CYP 3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>VELCADE</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>CYP 3A4</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>